ASTELLAS PHARMA/ADR Forecasted to Earn FY2025 Earnings of $2.76 Per Share (OTCMKTS:ALPMY)

ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) – Jefferies Financial Group issued their FY2025 earnings per share (EPS) estimates for shares of ASTELLAS PHARMA/ADR in a research report issued on Thursday, June 25th. Jefferies Financial Group analyst S. Barker anticipates that the company will post earnings per share of $2.76 for the year.

Several other research firms have also recently issued reports on ALPMY. Goldman Sachs Group upgraded shares of ASTELLAS PHARMA/ADR from a “neutral” rating to a “buy” rating in a report on Tuesday, May 26th. Zacks Investment Research cut ASTELLAS PHARMA/ADR from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, ValuEngine raised ASTELLAS PHARMA/ADR from a “sell” rating to a “hold” rating in a research note on Thursday, June 11th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $19.00.

ASTELLAS PHARMA/ADR stock opened at $16.66 on Monday. ASTELLAS PHARMA/ADR has a 52 week low of $12.48 and a 52 week high of $18.43. The stock has a market cap of $31.71 billion, a price-to-earnings ratio of 17.35 and a beta of 0.77. The company’s 50-day moving average price is $16.71 and its two-hundred day moving average price is $16.48. The company has a current ratio of 1.09, a quick ratio of 0.90 and a debt-to-equity ratio of 0.10.

ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17). The firm had revenue of $2.87 billion during the quarter.

ASTELLAS PHARMA/ADR Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent.

Featured Article: What Are Treasury Bonds?

Receive News & Ratings for ASTELLAS PHARMA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASTELLAS PHARMA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.